NASDAQ:ENTA

Enanta Pharmaceuticals Competitors

$50.68
-1.08 (-2.09 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$50.49
Now: $50.68
$52.46
50-Day Range
$47.82
MA: $50.46
$53.16
52-Week Range
$40.32
Now: $50.68
$58.59
Volume103,821 shs
Average Volume151,158 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.54

Competitors

Enanta Pharmaceuticals (NASDAQ:ENTA) Vs. ARNA, AGIO, AVIR, APLS, TPTX, and NKTR

Should you be buying ENTA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Enanta Pharmaceuticals, including Arena Pharmaceuticals (ARNA), Agios Pharmaceuticals (AGIO), Atea Pharmaceuticals (AVIR), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), and Nektar Therapeutics (NKTR).

Arena Pharmaceuticals (NASDAQ:ARNA) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Institutional & Insider Ownership

89.7% of Arena Pharmaceuticals shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 3.1% of Arena Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Arena Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Arena Pharmaceuticals and Enanta Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arena Pharmaceuticals001503.00
Enanta Pharmaceuticals13302.29

Arena Pharmaceuticals currently has a consensus price target of $92.80, indicating a potential upside of 40.82%. Enanta Pharmaceuticals has a consensus price target of $65.2857, indicating a potential upside of 28.82%. Given Arena Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Arena Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Profitability

This table compares Arena Pharmaceuticals and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arena PharmaceuticalsN/A-33.17%-30.41%
Enanta Pharmaceuticals-29.53%-3.75%-3.53%

Earnings & Valuation

This table compares Arena Pharmaceuticals and Enanta Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arena Pharmaceuticals$806.43 million4.93$397.55 million$7.698.57
Enanta Pharmaceuticals$122.47 million8.35$-36,170,000.00($0.89)-56.94

Arena Pharmaceuticals has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arena Pharmaceuticals beats Enanta Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Agios Pharmaceuticals (NASDAQ:AGIO) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Agios Pharmaceuticals and Enanta Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agios Pharmaceuticals$117.91 million32.38$-411,470,000.00($6.86)-7.97
Enanta Pharmaceuticals$122.47 million8.35$-36,170,000.00($0.89)-56.94

Enanta Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Agios Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Insider and Institutional Ownership

92.9% of Agios Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are owned by institutional investors. 3.2% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Agios Pharmaceuticals and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agios Pharmaceuticals-170.65%-57.63%-37.15%
Enanta Pharmaceuticals-29.53%-3.75%-3.53%

Analyst Recommendations

This is a summary of recent ratings for Agios Pharmaceuticals and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agios Pharmaceuticals03702.70
Enanta Pharmaceuticals13302.29

Agios Pharmaceuticals presently has a consensus target price of $64.6364, suggesting a potential upside of 18.19%. Enanta Pharmaceuticals has a consensus target price of $65.2857, suggesting a potential upside of 28.82%. Given Enanta Pharmaceuticals' higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Summary

Enanta Pharmaceuticals beats Agios Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Enanta Pharmaceuticals (NASDAQ:ENTA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Enanta Pharmaceuticals and Atea Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enanta Pharmaceuticals13302.29
Atea Pharmaceuticals00403.00

Enanta Pharmaceuticals presently has a consensus price target of $65.2857, suggesting a potential upside of 28.82%. Atea Pharmaceuticals has a consensus price target of $69.3333, suggesting a potential upside of 54.28%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Valuation & Earnings

This table compares Enanta Pharmaceuticals and Atea Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enanta Pharmaceuticals$122.47 million8.35$-36,170,000.00($0.89)-56.94
Atea PharmaceuticalsN/AN/AN/AN/AN/A

Atea Pharmaceuticals has lower revenue, but higher earnings than Enanta Pharmaceuticals.

Insider and Institutional Ownership

90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Enanta Pharmaceuticals and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enanta Pharmaceuticals-29.53%-3.75%-3.53%
Atea PharmaceuticalsN/AN/AN/A

Summary

Atea Pharmaceuticals beats Enanta Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Volatility & Risk

Apellis Pharmaceuticals has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Institutional and Insider Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Apellis Pharmaceuticals and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apellis PharmaceuticalsN/A-336.93%-78.28%
Enanta Pharmaceuticals-29.53%-3.75%-3.53%

Analyst Ratings

This is a breakdown of current ratings for Apellis Pharmaceuticals and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apellis Pharmaceuticals031112.87
Enanta Pharmaceuticals13302.29

Apellis Pharmaceuticals currently has a consensus price target of $125.00, suggesting a potential upside of 174.30%. Enanta Pharmaceuticals has a consensus price target of $65.2857, suggesting a potential upside of 28.82%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Apellis Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Valuation & Earnings

This table compares Apellis Pharmaceuticals and Enanta Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.82
Enanta Pharmaceuticals$122.47 million8.35$-36,170,000.00($0.89)-56.94

Enanta Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Turning Point Therapeutics (NASDAQ:TPTX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Turning Point Therapeutics and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Turning Point TherapeuticsN/A-23.81%-23.08%
Enanta Pharmaceuticals-29.53%-3.75%-3.53%

Risk and Volatility

Turning Point Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Insider and Institutional Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Turning Point Therapeutics and Enanta Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-24.42
Enanta Pharmaceuticals$122.47 million8.35$-36,170,000.00($0.89)-56.94

Enanta Pharmaceuticals has higher revenue and earnings than Turning Point Therapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Turning Point Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Turning Point Therapeutics and Enanta Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Turning Point Therapeutics00703.00
Enanta Pharmaceuticals13302.29

Turning Point Therapeutics presently has a consensus target price of $153.7143, indicating a potential upside of 110.48%. Enanta Pharmaceuticals has a consensus target price of $65.2857, indicating a potential upside of 28.82%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Turning Point Therapeutics is more favorable than Enanta Pharmaceuticals.

Summary

Turning Point Therapeutics beats Enanta Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Nektar Therapeutics (NASDAQ:NKTR) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Nektar Therapeutics and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nektar Therapeutics16102.00
Enanta Pharmaceuticals13302.29

Nektar Therapeutics currently has a consensus price target of $25.2857, indicating a potential upside of 33.08%. Enanta Pharmaceuticals has a consensus price target of $65.2857, indicating a potential upside of 28.82%. Given Nektar Therapeutics' higher probable upside, equities research analysts plainly believe Nektar Therapeutics is more favorable than Enanta Pharmaceuticals.

Valuation & Earnings

This table compares Nektar Therapeutics and Enanta Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$114.62 million30.22$-440,670,000.00($2.52)-7.54
Enanta Pharmaceuticals$122.47 million8.35$-36,170,000.00($0.89)-56.94

Enanta Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.3% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Nektar Therapeutics and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nektar Therapeutics-269.05%-30.74%-22.63%
Enanta Pharmaceuticals-29.53%-3.75%-3.53%

Volatility & Risk

Nektar Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Summary

Enanta Pharmaceuticals beats Nektar Therapeutics on 9 of the 14 factors compared between the two stocks.


Enanta Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69-0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94-2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57-1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03-5.8%$3.58 billionN/A-20.81Analyst Report
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00-0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59-0.8%$3.42 billion$306.98 million-6.95
Insmed logo
INSM
Insmed
1.2$33.07-1.7%$3.42 billion$136.47 million-12.72News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15-0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87-1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69-2.6%$3.16 billion$42.98 million-25.27Analyst Upgrade
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60-4.2%$3.04 billionN/A-56.02Insider Selling
MorphoSys logo
MOR
MorphoSys
0.3$22.65-2.3%$2.98 billion$80.43 million107.86Decrease in Short Interest
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64-1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46-5.3%$2.75 billion$260.98 million-357.67Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00-0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39-0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81-1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22-3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26-5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73-0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57-2.6%$2.35 billion$33.94 million-88.91
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13-5.6%$2.35 billion$15 million-17.35Unusual Options Activity
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22-0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96-1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68-0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15-0.3%$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44-1.6%$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02-0.2%$1.98 billion$429.76 million-100.38Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22-3.5%$1.94 billion$410,000.00-5.92Analyst Report
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$59.69-4.6%$1.91 billionN/A-25.40Increase in Short Interest
MacroGenics logo
MGNX
MacroGenics
1.2$31.83-2.4%$1.91 billion$64.19 million-10.17Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.73-3.2%$1.90 billion$34.51 million-17.72
Kura Oncology logo
KURA
Kura Oncology
1.6$28.59-3.1%$1.89 billionN/A-17.54
FibroGen logo
FGEN
FibroGen
1.8$19.91-3.1%$1.82 billion$256.58 million-7.63Analyst Report
High Trading Volume
News Coverage
MORF
Morphic
1.3$55.08-0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70-0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89-0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.